𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Anthocyanins and their metabolites are weak inhibitors of cytochrome P450 3A4

✍ Scribed by Andrea Dreiseitel; Peter Schreier; Anett Oehme; Sanja Locher; Goeran Hajak; Philipp G. Sand


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
338 KB
Volume
52
Category
Article
ISSN
1613-4125

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The cytochrome P450 enzyme cytochrome P450 3A4 (CYP3A4) controls the metabolism of about 60% of all drugs, and its inhibition may dramatically affect drug safety. Modulation of cytochrome P450 activity has been observed by constituents of fruit extracts including several flavonoids. The present investigation addresses CYP3A4 inhibition by anthocyanins, their aglycons, proanthocyanidins, and phenolic metabolites using a chemiluminescent assay. Test compounds inhibited CYP3A4 activity in a concentration‐dependent manner featuring IC~50~ values from 12.2 up to 7,842 ΞΌM. In the order of decreasing effect size, anthocyanidins were followed by anthocyanins, proanthocyanidins, and phenolic acids. When compared to earlier data on furanocoumarins from grapefruit extract, the inhibitory activity of tested anthocyanins, and anthocyanidins was shown to be about 10 000‐fold weaker, and was negligible for phenolic acids (>100Β 000‐fold weaker). Future studies are invited to address effects of the above flavonoids on other CYP isoforms for more detailed toxicity profiles.


πŸ“œ SIMILAR VOLUMES


A Panel of Cytochrome P450 BM3 Variants
✍ Andrewβ€…M. Sawayama; Michaelβ€…M.β€…Y. Chen; Palaniappan Kulanthaivel; Ming-Shang Kuo πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 251 KB

## Abstract Herein we demonstrate that a small panel of variants of cytochrome P450 BM3 from __Bacillus megaterium__ covers the breadth of reactivity of human P450s by producing 12 of 13 mammalian metabolites for two marketed drugs, verapamil and astemizole, and one research compound. The most acti

Cytokines influence mRNA expression of c
✍ Petra Maria Bertilsson; Patrik Olsson; Karl-Eric Magnusson πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 1 views

Inflammation and infection may have the potential to increase the bioavailability of drugs. This effect could be because of a reduced metabolism of xenobiotics in the liver and/or the intestines, or because of alterations in small intestinal permeability, mucosal flow, and expression of drug efflux